FR2351092B1 - - Google Patents

Info

Publication number
FR2351092B1
FR2351092B1 FR7714262A FR7714262A FR2351092B1 FR 2351092 B1 FR2351092 B1 FR 2351092B1 FR 7714262 A FR7714262 A FR 7714262A FR 7714262 A FR7714262 A FR 7714262A FR 2351092 B1 FR2351092 B1 FR 2351092B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7714262A
Other versions
FR2351092A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of FR2351092A1 publication Critical patent/FR2351092A1/fr
Application granted granted Critical
Publication of FR2351092B1 publication Critical patent/FR2351092B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fodder In General (AREA)
FR7714262A 1976-05-11 1977-05-10 Polypeptides ayant une activite agoniste de la luliberine Granted FR2351092A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB19327/76A GB1524747A (en) 1976-05-11 1976-05-11 Polypeptide

Publications (2)

Publication Number Publication Date
FR2351092A1 FR2351092A1 (fr) 1977-12-09
FR2351092B1 true FR2351092B1 (fr) 1980-02-22

Family

ID=10127509

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7714262A Granted FR2351092A1 (fr) 1976-05-11 1977-05-10 Polypeptides ayant une activite agoniste de la luliberine

Country Status (27)

Country Link
US (1) US4100274A (fr)
JP (1) JPS52136172A (fr)
AT (2) AT379400B (fr)
AU (1) AU508025B2 (fr)
BE (1) BE854467A (fr)
BG (1) BG60740B2 (fr)
CA (1) CA1101844A (fr)
CH (2) CH627151A5 (fr)
CS (1) CS199673B2 (fr)
DD (1) DD136738A5 (fr)
DE (1) DE2720245C2 (fr)
DK (1) DK149596C (fr)
ES (1) ES458691A1 (fr)
FI (1) FI64139C (fr)
FR (1) FR2351092A1 (fr)
GB (1) GB1524747A (fr)
HU (1) HU179990B (fr)
IE (1) IE44426B1 (fr)
IL (1) IL52014A (fr)
NL (2) NL191793C (fr)
NO (2) NO147304C (fr)
NZ (1) NZ183931A (fr)
PL (2) PL104362B1 (fr)
SE (2) SE437837B (fr)
SU (1) SU910116A3 (fr)
YU (1) YU40672B (fr)
ZA (1) ZA772433B (fr)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
DE3411224A1 (de) * 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4705778A (en) * 1985-10-22 1987-11-10 Sri International Orally active LHRH analogs
JPH0284272U (fr) * 1988-12-20 1990-06-29
JP2672677B2 (ja) * 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
PH30747A (en) * 1989-03-10 1997-10-17 Endorech Inc Combination therapy for the treatment of estrogen sensitive disease.
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
CA2062792C (fr) * 1989-07-07 2006-03-21 Fernard Labrie Traitement des maladies liees aux androgenes
ES2121570T3 (es) * 1989-07-07 1998-12-01 Endorecherche Inc Derivados de androgenos para uso en la inhibicion de la actividad de los esteroides sexuales.
GB9112859D0 (en) * 1991-06-14 1991-07-31 Ici Plc Peptide process
EP0641211A1 (fr) * 1992-05-21 1995-03-08 Endorecherche Inc. INHIBITEURS D'ACTIVITE DE LA TESTOSTERONE 5$g(a)-REDUCTASE
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
CA2192782C (fr) 1995-12-15 2008-10-14 Nobuyuki Takechi Production de microsphere
CA2192773C (fr) 1995-12-15 2008-09-23 Hiroaki Okada Obtention d'une preparation a liberation prolongee pour injection
WO1999007874A1 (fr) * 1996-06-13 1999-02-18 Itoham Foods Inc. Procede de production de derives de lh-rh
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
ES2154590B1 (es) 1999-05-20 2001-11-01 Lipotec Sa Procedimiento de sintesis de peptidos en fase solida
AR023940A1 (es) 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
EP2762140B1 (fr) 2001-02-19 2017-03-22 Novartis AG Traitement de tumeurs solides du cerveau avec un dérivé de la rapamycine
CZ299756B6 (cs) 2001-05-16 2008-11-12 Novartis Ag Kombinace s obsahem N-{5-[4-(4-methyl-piperazino-methyl)benzoylamido]-2-methylfenyl}-4-(3-pyridyl)-2-pyrimidin-aminu k lécení proliferativních onemocnení
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
WO2003041739A1 (fr) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Agents anticancer
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
DK1505959T3 (da) 2002-05-16 2009-02-23 Novartis Ag Anvendelse af EDG-receptorbindingsmidler ved cancer
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CN101797221B (zh) 2002-12-13 2013-06-12 杜雷科特公司 包含高粘度液体载体材料的口服递药系统
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
NZ549925A (en) 2004-04-07 2010-08-27 Novartis Ag Inhibitors of IAP
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
AU2005257484A1 (en) * 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
SI2767292T1 (sl) 2004-09-17 2017-01-31 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
US20090036435A1 (en) 2005-01-21 2009-02-05 Astex Therapeutics Limited Pharmaceutical Compounds
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
EP2119725A1 (fr) 2005-05-03 2009-11-18 Novetide Ltd. Méthode de préparation de la leuprolide
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2007038459A2 (fr) 2005-09-27 2007-04-05 Novartis Ag Composes de carboxyamine et leurs methodes d'utilisation
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
NZ572299A (en) 2006-05-09 2010-07-30 Novartis Ag Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof
WO2008037477A1 (fr) 2006-09-29 2008-04-03 Novartis Ag PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
EP2073807A1 (fr) 2006-10-12 2009-07-01 Astex Therapeutics Limited Combinaisons pharmaceutiques
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
ES2388355T3 (es) 2006-11-03 2012-10-11 Durect Corporation Sistemas de suministro transdémico que comprenden bupivacaína
EP2120900A2 (fr) 2007-02-15 2009-11-25 Novartis AG Combinaisons d'agents thérapeutiques pour le traitement du cancer
AU2008347158B8 (en) 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
CN102036953B (zh) 2008-03-24 2015-05-06 诺华股份有限公司 基于芳基磺酰胺的基质金属蛋白酶抑制剂
EA019033B1 (ru) 2008-03-26 2013-12-30 Новартис Аг Ингибиторы дезацетилазы в, основанные на гидроксамате
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
HUE031367T2 (en) * 2008-11-28 2017-07-28 Novartis Ag A pharmaceutical combination comprising an Hsp 90 inhibitor and a mTOR inhibitor
WO2010083617A1 (fr) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines en tant qu'inhibiteurs de protéines kinases
WO2010088335A1 (fr) 2009-01-29 2010-08-05 Novartis Ag Benzimidazoles substitués destinés au traitement d'astrocytomes
ES2475945T3 (es) 2009-06-26 2014-07-11 Novartis Ag Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
CA2771432A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composes d'oximes heterocycliques
JP2013503129A (ja) 2009-08-26 2013-01-31 ノバルティス アーゲー テトラ−置換ヘテロアリール化合物ならびにｍｄｍ２および／またはｍｄｍ４モジュレーターとしてのそれらの使用
CA2773661A1 (fr) 2009-09-10 2011-03-17 Novartis Ag Derives ethers d'heteroaryles bicycliques
CN102596951B (zh) 2009-11-04 2015-04-15 诺华股份有限公司 用作mek抑制剂的杂环磺酰胺衍生物
EP2504339A1 (fr) 2009-11-25 2012-10-03 Novartis AG Dérivés hétérocycliques d'hétéroaryles bicycliques à 6 cycles benzéniques accolés de benzène contenant de l'oxygène
US8614239B2 (en) 2009-12-08 2013-12-24 Novartis Ag Heterocyclic sulfonamide derivatives
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
MX2012014579A (es) 2010-06-16 2013-05-22 Endorech Inc Procedimientos de tratamiento o pevencion de enfermedades relacionadas con estrogenos.
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
JP2013528635A (ja) 2010-06-17 2013-07-11 ノバルティス アーゲー ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
WO2012035078A1 (fr) 2010-09-16 2012-03-22 Novartis Ag Inhibiteurs de la 17α-hydroxylase/c17,20-lyase
WO2012107500A1 (fr) 2011-02-10 2012-08-16 Novartis Ag Composés de [1, 2, 4] triazolo [4, 3 -b] pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
CN103492390A (zh) 2011-03-08 2014-01-01 诺瓦提斯公司 氟苯基双环杂芳基化合物
CA2834224A1 (fr) 2011-04-28 2012-11-01 Novartis Ag Inhibiteurs de 17.alpha.-hydroxylase/c17,20-lyase
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
JP2014517004A (ja) 2011-06-09 2014-07-17 ノバルティス アーゲー 複素環スルホンアミド誘導体
EP2721008B1 (fr) 2011-06-20 2015-04-29 Novartis AG Dérivés de isoquinolinone substitués par un radical hydroxylé en tant que inhibiteurs de p53 (mdm2 or mdm4)
WO2012175487A1 (fr) 2011-06-20 2012-12-27 Novartis Ag Composés de cyclohexyl-isoquinolinone
SG195067A1 (en) 2011-06-27 2013-12-30 Novartis Ag Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
CN104080787B (zh) 2011-11-29 2016-09-14 诺华股份有限公司 吡唑并吡咯烷化合物
SG11201402237WA (en) 2011-12-22 2014-09-26 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
EP2794594A1 (fr) 2011-12-22 2014-10-29 Novartis AG Dérivés quinoline
KR20140104047A (ko) 2011-12-23 2014-08-27 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
US20140357666A1 (en) 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
WO2013096049A1 (fr) 2011-12-23 2013-06-27 Novartis Ag Composés permettant d'inhiber l'interaction de bcl-2 avec des partenaires de liaison
US20140357633A1 (en) 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
US20140350014A1 (en) 2011-12-23 2014-11-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
US20130310387A1 (en) 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
CN104321325B (zh) 2012-05-24 2016-11-16 诺华股份有限公司 吡咯并吡咯烷酮化合物
US9789193B2 (en) 2012-06-15 2017-10-17 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
EP2882747B1 (fr) 2012-08-13 2016-04-27 Novartis AG Dérivés hétéroaryle cycloalkyldiamine bicycliques en tant qu'inhibiteurs de tyrosine kinases de la rate (syk)
CA2885969C (fr) 2012-10-02 2021-04-06 Epitherapeutics Aps Derives de pyridine substitues et leurs compositions utiles comme inhibiteurs d'histone demethylases
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
WO2014115080A1 (fr) 2013-01-22 2014-07-31 Novartis Ag Composés pyrazolo[3,4-d]pyrimidinone utilisés en tant qu'inhibiteurs de l'interaction p53/mdm2
EP2948451B1 (fr) 2013-01-22 2017-07-12 Novartis AG Composés de purinone substitués
WO2014128612A1 (fr) 2013-02-20 2014-08-28 Novartis Ag Dérivés de quinazolin-4-one
US9650339B2 (en) 2013-02-27 2017-05-16 Gilead Sciences, Inc. Inhibitors of histone demethylases
WO2014144975A1 (fr) 2013-03-15 2014-09-18 Durect Corporation Compositions ayant un agent de modification rhéologique pour réduire une variabilité de dissolution
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (fr) 2013-08-14 2015-02-19 Novartis Ag Composés et compositions utiles comme inhibiteurs de mek
WO2015022664A1 (fr) 2013-08-14 2015-02-19 Novartis Ag Composés et compositions utiles comme inhibiteurs de mek
SG11201600028YA (en) 2013-09-22 2016-02-26 Calitor Sciences Llc Substituted aminopyrimidine compounds and methods of use
US20160331755A1 (en) 2014-01-15 2016-11-17 Samit Hirawat Pharmaceutical Combinations
CA2943979A1 (fr) 2014-03-28 2015-10-01 Calitor Sciences, Llc Composes heteroaryle substitues et leurs methodes d'utilisation
JP2017512804A (ja) 2014-03-31 2017-05-25 ギリアード サイエンシーズ， インコーポレイテッド ヒストン脱メチル化酵素の阻害剤
CA2944401A1 (fr) 2014-04-03 2015-10-08 Invictus Oncology Pvt. Ltd. Agents therapeutiques combinatoires supramoleculaires
BR112017003442A2 (pt) 2014-08-27 2017-11-28 Gilead Sciences Inc compostos e métodos para inibir histona desmetilases
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
EP3730483B1 (fr) 2017-12-21 2023-08-30 Hefei Institutes of Physical Science, Chinese Academy of Sciences Classe d'inhibiteurs de kinase dérivés de pyrimidine
CA3083040A1 (fr) 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Composes d'aminopyrimidine substitues et procedes d'utilisation
AU2020356605A1 (en) * 2019-09-26 2022-04-14 S.I.S. Shulov Innovative Science Ltd. Anti-aging compositions and methods of use thereof
WO2021097256A1 (fr) 2019-11-14 2021-05-20 Cohbar, Inc. Peptides antagonistes de cxcr4
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US4005063A (en) * 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
US3901872A (en) * 1974-03-13 1975-08-26 American Home Prod P-glu-his-trp-ser-tyr-d-pgl-leu-arg-pro-gly-nh' 2 'and intermediates
JPS50142563A (fr) * 1974-04-26 1975-11-17
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US3971737A (en) * 1975-03-24 1976-07-27 American Home Products Corporation [2-Methyl-Ala6 ]LRH
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4024121A (en) * 1976-01-27 1977-05-17 Schally Andrew Victor (Pyro)-Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR and intermediates
US4018726A (en) * 1975-06-12 1977-04-19 Andrew Victor Schally [D-Phe6 ]-LH-RH and intermediates therefor
US3992530A (en) * 1975-12-08 1976-11-16 American Home Products Corporation [D-2-(1,4-Cyclohexadienyl)gly]6 -des-gly10 -lrh nonapeptide amides

Also Published As

Publication number Publication date
NZ183931A (en) 1979-03-16
GB1524747A (en) 1978-09-13
IL52014A0 (en) 1977-07-31
IE44426B1 (en) 1981-11-18
AT379400B (de) 1985-12-27
NL970002I1 (nl) 1997-03-03
SE437993B (sv) 1985-03-25
ZA772433B (en) 1978-03-29
IE44426L (en) 1977-11-11
HU179990B (en) 1983-01-28
PL104362B1 (pl) 1979-08-31
YU117277A (en) 1983-02-28
FI64139C (fi) 1983-10-10
AT365562B (de) 1982-01-25
DK149596C (da) 1987-01-05
US4100274A (en) 1978-07-11
ES458691A1 (es) 1978-08-16
CA1101844A (fr) 1981-05-26
JPS52136172A (en) 1977-11-14
NL970002I2 (nl) 1997-05-01
FI771480A (fr) 1977-11-12
FR2351092A1 (fr) 1977-12-09
NL191793B (nl) 1996-04-01
CS199673B2 (en) 1980-07-31
BE854467A (fr) 1977-11-10
NO149586C (no) 1984-05-16
AU2468177A (en) 1978-11-02
DE2720245A1 (de) 1977-11-24
ATA217979A (de) 1981-06-15
PL197889A1 (pl) 1978-02-13
YU40672B (en) 1986-04-30
DK149596B (da) 1986-08-04
NO147304C (no) 1983-03-16
NO149586B (no) 1984-02-06
NO822984L (no) 1977-11-14
CH629475A5 (de) 1982-04-30
PL108860B1 (en) 1980-05-31
FI64139B (fi) 1983-06-30
NO771644L (no) 1977-11-14
AU508025B2 (en) 1980-03-06
CH627151A5 (fr) 1981-12-31
ATA335877A (de) 1985-05-15
SU910116A3 (ru) 1982-02-28
NL191793C (nl) 1996-08-02
NO147304B (no) 1982-12-06
JPS6113480B2 (fr) 1986-04-14
SE8007763L (sv) 1980-11-05
DK207977A (da) 1977-11-12
IL52014A (en) 1979-11-30
DE2720245C2 (de) 1986-09-25
SE437837B (sv) 1985-03-18
DD136738A5 (de) 1979-07-25
NL7705130A (nl) 1977-11-15
SE7705432L (sv) 1977-11-12
BG60740B2 (bg) 1996-01-31

Similar Documents

Publication Publication Date Title
FR2351092B1 (fr)
FI770187A (fr)
JPS5528861B2 (fr)
JPS5349776U (fr)
JPS5618574Y2 (fr)
JPS5370961U (fr)
JPS568366Y2 (fr)
JPS5633878B2 (fr)
JPS52110860U (fr)
JPS5360087U (fr)
BR5600715U (fr)
JPS5344752U (fr)
JPS5348756U (fr)
CS177780B1 (fr)
JPS52170776U (fr)
JPS52102094U (fr)
DK571976A (fr)
CH611512A5 (fr)
CH611597A5 (fr)
CH599714A5 (fr)
CH598779A5 (fr)
CH595902A5 (fr)
CH598932A5 (fr)
CH598954A5 (fr)
DD123772A1 (fr)

Legal Events

Date Code Title Description
CC Supplementary protection certificate (spc) laid open to the public (law of 25 june 1990)

Free format text: 92C0196, 920513

CB Supplementary protection certificate (spc) granted (law of 25 june 1990)

Free format text: 92C0196, 770510

CL Concession to grant licences
TP Transmission of property
CP Supplementary protection certificate (spc) filed

Free format text: 93C0043, 930628

CR Request for supplementary protection certificate laid open to the public (eec regulation of 18 june 1992)

Free format text: 93C0043, 930628

CP Supplementary protection certificate (spc) filed
CX Request for supplementary protection certificate (spc) rejected

Free format text: 93C0043, 930628